<DOC>
	<DOCNO>NCT02179502</DOCNO>
	<brief_summary>The purpose First-in-Human study evaluate safety tolerability single ascend oral dos GLPG1690 give healthy male subject , compare placebo . Also , safety tolerability multiple ascend oral dos GLPG1690 give healthy male subject daily 14 day compare placebo , evaluate . Furthermore , course study single multiple oral dose administration , amount GLPG1690 present blood urine ( pharmacokinetics ) well reduction biomarker level GLPG1690 plasma sample ( pharmacodynamics ) characterize compare placebo . The pharmacokinetics solid dosage formulation GLPG1690 compare liquid dosage formulation GLPG1690 . Also , potential cytochrome P450 ( CYP ) 3A4 induction repeat dose GLPG1690 explore .</brief_summary>
	<brief_title>First-in-Human Single Multiple Dose GLPG1690</brief_title>
	<detailed_description />
	<criteria>Healthy male , age 1850 year BMI 1830 kg/m2 Any condition might interfere procedure test study Drug alcohol abuse Smoking</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>